GET DAILY SIGNALSAvantor (AVTR) Advances +6% on Steady Turnaround Momentum
Key Takeaways
- Avantor (AVTR) traded near $16.27 in late October 2026, up roughly 6% from its level 30 days earlier, reflecting a steady uptrend rather than a sharp, volatile spike.
- Third-quarter 2026 results marked a return to organic revenue growth of 5.2%, with net sales of $1.70 billion rising 4.6% year over year and exceeding consensus estimates.
- Both operating segments expanded: VWR Distribution & Services grew 5.8% organically, while Bioscience & Medtech Products returned to growth at 3.6%.
- Management raised full-year 2026 guidance for organic revenue growth, adjusted earnings per share, and free cash flow, citing improving execution and stronger end markets.
- The company's "Revival" program — focused on commercial execution, digital capabilities, and cost discipline — sits at the center of the improving operating trend.
- Analyst sentiment remains mixed, with a consensus Hold rating and average price targets generally below the prevailing share price.
- For deeper context on valuation and forward estimates, explore Avantor's Price Targets, Earnings, and Forecast pages.
- Investors seeking systematic, data-driven trading ideas can also explore Tickeron's Trending AI Robots.
Market Snapshot for AVTR
Shares of AVTR have moved higher in a measured way over the past month, posting gains of roughly 6% while the broader market advanced more modestly. The stock has outperformed the S&P 500 on a year-to-date basis, supported by the return to revenue growth and a string of quarterly earnings beats. Market capitalization stands near $11.6 billion, and institutional interest has been evident, with several large asset managers increasing positions in the second quarter.
Even with the upward move, sell-side analysts remain largely neutral. The consensus rating is Hold, and the average 12-month price target sits below the current price, suggesting that much of the near-term optimism around the turnaround may already be priced in.
Business Overview and Competitive Position
Avantor, Inc., based in Radnor, Pennsylvania, supplies mission-critical products and services to the life sciences and advanced technology sectors. The company reaches more than 300,000 customer locations in 180 countries, providing laboratory consumables, chemicals, equipment, and related services that support research, development, and production.
Operations are divided into two main segments. The VWR Distribution & Services segment supplies lab materials and services to biopharmaceutical, healthcare, education, and government clients. The Bioscience & Medtech Products segment offers proprietary materials such as process chemicals and high-performance silicone products used in bioprocessing and medical device manufacturing.
Scale, a broad portfolio, and deep integration into customer supply chains represent key advantages. AVTR also serves as a useful indicator of global R&D spending trends, which is why it draws attention from investors tracking the life sciences tools cycle.
Recent Results and Guidance Updates
The main driver over the past month was the third-quarter 2026 earnings release. Net sales reached $1.698 billion, up 4.6% reported and 5.2% organically, beating consensus estimates of about $1.64 billion. Adjusted earnings per share of $0.22 also exceeded expectations. GAAP net income came in at $203.4 million, a notable improvement from the prior-year net loss of $711.8 million that included a large impairment charge.
Management noted stronger momentum in the VWR segment and the return to organic growth in Bioscience & Medtech Products. As a result, full-year 2026 guidance was raised: organic revenue growth to 0.75%–1.25%, adjusted EPS to $0.81–$0.83, and free cash flow to $525 million–$550 million.
Leadership transitions included a new chief financial officer in September and a new chief information officer in late October, rounding out the team behind the Revival program. Several analysts lifted price targets during the month, though the overall consensus stayed at Hold. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
2026 Outlook and Key Areas to Watch
The central question going forward is whether the return to organic growth can be sustained and expanded. It will be important to see continued progress in the VWR segment from better commercial execution and whether Bioscience & Medtech Products can maintain its positive trend as supply-chain and throughput initiatives develop further.
End-market conditions remain a focus. Management has highlighted improving demand from large pharmaceutical and biotechnology customers, early signs of recovery in higher education and early-stage biotech, and steady activity in select industrial areas. Europe continues to lag, so any pickup there would provide an additional boost.
Balance-sheet improvement is another point of attention, with a target adjusted net leverage ratio below 3x by year-end. Macro risks such as foreign-exchange fluctuations, cost pressures, and funding challenges for government-supported research could still affect results. The cautious analyst stance, reflected in the Hold consensus and price targets below the current level, indicates that further gains will likely require ongoing execution and evidence of durable, broad-based growth.
Exploring Systematic Trading Approaches
In my own research, I often look at quantitative signals to complement fundamental analysis. Tickeron’s AI Trading Bots offer a range of automated strategies across many tickers, allowing users to review performance metrics, holding periods, and risk characteristics side by side. This can help identify approaches that align with individual objectives without relying solely on discretionary decisions.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for AVTR turns positive, indicating new upward trend
AVTR saw its Momentum Indicator move above the 0 level on October 05, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 89 similar instances where the indicator turned positive. In 61 of the 89 cases, the stock moved higher in the following days. The odds of a move higher are at 69%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for AVTR just turned positive on October 15, 2026. Looking at past instances where AVTR's MACD turned positive, the stock continued to rise in 28 of 45 cases over the following month. The odds of a continued upward trend are 62%.
Following a +5.96% 3-day Advance, the price is estimated to grow further. Considering data from situations where AVTR advanced for three days, in 172 of 273 cases, the price rose further within the following month. The odds of a continued upward trend are 63%.
The Aroon Indicator entered an Uptrend today. In 112 of 174 cases where AVTR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 64%.
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AVTR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 73%.
AVTR broke above its upper Bollinger Band on October 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 23 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.058) is normal, around the industry mean (4.942). P/E Ratio (-20.153) is within average values for comparable stocks, (37.224). Projected Growth (PEG Ratio) (0.840) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (1.614) is also within normal values, averaging (56.876).
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. AVTR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 93 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 99 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AVTR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of laboratory chemicals
Industry PharmaceuticalsOther
Advertisement